Financial Comparison: Onion Global (NYSE:OG) vs. LogicBio Therapeutics (OTCMKTS:LOGC)

Profitability

This table compares Onion Global and LogicBio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Onion Global	N/A	N/A	N/A
LogicBio Therapeutics	N/A	-20.68%	-13.18%

Institutional & Insider Ownership

2.6% of Onion Global shares are held by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are held by institutional investors. 50.9% of Onion Global shares are held by company insiders. Comparatively, 0.5% of LogicBio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Onion Global has a beta of -3.42, meaning that its stock price is 442% less volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Earnings & Valuation

This table compares Onion Global and LogicBio Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onion Global	$2.04 billion	0.00	-$55.90 million	N/A	N/A
LogicBio Therapeutics	$43.00 million	9.29	-$29.00 million	($1.09)	-8.03

LogicBio Therapeutics has lower revenue, but higher earnings than Onion Global.

About Onion Global

Onion Global Limited operates a platform that incubates, markets, and distributes fashionable and future brands in China and internationally. Its platform comprises brand partners that offer various categories of lifestyle products, including beauty products, maternal and baby products, food and beverages, fast fashion, and wellness products. The company was incorporated in 2009 and is based in Guangzhou, the People's Republic of China.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.